Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Imetelstat in high-risk triple-negative myelofibrosis

Jean-Jacques Kiladjian • 15 Jun 2020
EHA 2020
Myelofibrosis Myeloproliferative Neoplasms Ruxolitinib

Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Paris Diderot University, Paris, France, discusses the use of imetelstat, a telomerase inhibitor, as evaluated in a Phase II randomized study investigating its use (NCT02426086). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jean-Jacques Kiladjian

16:35
Key highlights in MPNs at ASH 2023: novel agents & combinations, ongoing clinical trials, and more
Claire Harrison et al. • 11 Dec 2023
2:31
The growing role of combination approaches in MF & agents being explored
Jean-Jacques Kiladjian • 9 Oct 2023
4:35
The role of JAK2 VAF testing in risk assessment and disease monitoring in MPNs
Jean-Jacques Kiladjian • 13 Jun 2023
2:14
Ruxolitinib combinations in patients with myelofibrosis
Jean-Jacques Kiladjian • 26 Apr 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals